Allen & Overy advises GSK on the sale of Lucozade and Ribena to Suntory
Allen & Overy has advised GlaxoSmithKline (GSK) on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage and Food Ltd (Suntory), the Japanese consumer goods company, for £1.35bn.
It is expected that the transaction will be completed by the end of the year, subject to regulatory approvals.
Under the agreement, Suntory will acquire global rights to the brands with the exception of Nigeria, where GSK Nigeria will continue to manufacture and distribute Lucozade and Ribena under licence from Suntory.
In addition, Suntory will acquire GSK’s Coleford manufacturing site, which is located in the Forest of Dean in the UK. The vast majority of existing employees at the site will transfer to Suntory under the provisions of English employment law.
The Allen & Overy team was led by corporate partners Ed Barnett and Andrew Ballheimer, with assistance from Matthew Appleton and Nigel Parker.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
A new Luxembourg act on the immobilisation of bearer shares and units was published in the Luxembourg Official Gazette on 14 August 2014.
OFAC has issued revised guidance relating to the status of entities owned by individuals or entities whose interests in property are blocked under executive orders.
Analysis from The Lawyer
At the time of its launch Accutrainee was described as a revolutionary change to the training model. Has it proved to be so? Not really.
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.